Conférences  >  Médecine & Soins de Santé  >  Cancérologie

ESMO - European Society for Medical Oncology

The ESMO Asia Congress 2023 will welcome you in Singapore from 1 to 3 December, to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level, and for the Asia-Pacific region. The outstanding scientific programme will cover the latest advances on the most prevalent cancer types in the region, offering high quality multidisciplinary educational sessions and special sessions in collaboration with illustrious international and Asia-Pacific oncology associations.

As usual, there will be a special focus on the Pan-Asian Guidelines Adaptation (PAGA) Lectures, conceived to share best practice standards of care for cancer patients and providing a framework for the structured interaction of key opinion leaders in oncology from Asia and Europe.

We hope you will be part of that journey by attending ESMO Asia 2023, where we will unite the Asian and global oncology community and share unforgettable moments!

Email.: asiacongress@esmo.org

Breast cancer, CNS, Developmental and precision medicine, gastrointestinal tumours, genitourinary tumours, gynaecological malignancies, head and neck cancer, investigational immunotherapy, melanoma, public policy, sarcoma, rare tumours, thoracic cancer, oncology

Pharmacogénétique, Médecine personnalisée,    Médecine translationnelle, essais cliniques

The European Association for Cancer Research (EACR) and AstraZeneca

Epigenetic control is essential for development and differentiation, and this control mechanism is very frequently deregulated in cancer. Several small molecule inhibitors have been developed in recent years that have either been approved for clinical use or are in preclinical and clinical trials. This conference will focus on basic and clinical aspects of targeting a broad panel of epigenetic proteins in cancer, either as monotherapies, or as combination therapies, including the use of immune checkpoint inhibitors to increase drug sensitivity and overcome chemoresistance.

Tél.: [N/A];     Email.: hannah.barrs@eacr.org

epigenetics, molecule inhibitors, epigenetic proteins in cancer, monotherapies, combination therapies, immune checkpoint inhibitors, drug discovery, drug sensitivity, chemoresistance, genetically targeted cancer therapy, novel epigenetic targets, drug resistance, clinical cancer trials, cancer research, oncology

Binaytara foundation

Disparities in hematologic cancers can manifest in various ways, including differences in incidence, access to care, treatment outcomes, and survival rates among diverse population groups. Addressing these disparities is essential for providing equitable patient care and improving overall outcomes.

Tél.: [6192392200];     Email.: yoadan.h@binayfoundation.org

Hematology, Oncology, Cancer, Clinical trial, Cancercare, Healthcare

Binaytara foundation

The Best of ASH & SABCS 2024, Seattle is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders & breast cancer.

Tél.: [425-616-0572];     Email.: yoadan.h@binayfoundation.org

ASH & SABCS 2024, Oncology, ASH Annual meeting 2024, Cancer, Breast Cancer, Clinical outcome

Binaytara Foundation

The Best of ASH & SABCS 2024, Phoenix is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders & breast cancer.

Tél.: [4252746864];     Email.: yoadan.h@binayfoundation.org

Hematology, oncology, ASH2024, SABCS2024, Breast cancer, Clinical outcome

Binaytara foundation

The Best of ASH & SABCS 2024, Portland, is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders & breast cancer.

Tél.: [425-616-0572];     Email.: yoadan.h@binayfoundation.org

Hematologists, Oncologists, Surgeons, Hematologic disorders, Breast cancer, ASH2024, SABC2024

Binaytara foundation

The BTF Best of ASH & SABCS 2024, Houston is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders & breast cancer.

This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders and breast cancer with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients.

Tél.: [425-616-0572];     Email.: yoadan.h@binayfoundation.org

Hematology, Oncology, Cancer, ASH2024, SABCS2024, Diagnosis, clinical trials

The European Association for Cancer Research (EACR), in conjunction with the European Molecular Biology Organisation (EMBO)

The EACR, in partnership with EMBO, is launching a new virtual conference for those working in cancer research in an academic environment who are considering at some point in the future taking their research private by starting their own company. Wherever you are in your academic career, if you think you might like to commercialise your research in the future then this conference is for you!

This conference aims to act as a ‘starter pack’ and will encompass a collection of powerful personal examples, advice from people who have done it, and representatives of relevant industries. It aims to inform participants of the steps that need to be considered when making the decision to commercialise academic research and the opportunities available.

The target audience for this conference is researchers working in academia who are considering commercialising their research, whether now or in the future.

Conference Officer: Chris Iliffe;     Tél.: [N/A];     Email.: christopher.iliffe@eacr.org

cancer research, oncology, research funding, legal advice for cancer researchers, privatising research, moving from academia to business, career progression, cancer research careers

Binaytara foundation

The Best of ASH & SABCS 2024, Albuquerque, is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders and breast cancer. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care. This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders and breast cancer with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients.

Tél.: [425-616-0572];     Email.: yoadan.h@binayfoundation.org

oncology, hematology, cancer, BEST OF ASH, Cancer Conference

The PAMM EORTC meeting is a unique blend of translational and clinical research in oncology – covering the latest innovations in targeted therapies and immunotherapies, experimental therapeutics, precision medicine and cutting-edge oncology. Invited speakers include opinion leaders in their respective fields, either as clinical investigators or researchers – plus a selection of abstracts presented by young scientists and private symposia sponsored by pharmaceutical partners covering the latest advances in cancer treatment.

The European Association for Cancer Research (EACR)

Discover the hidden world of cancer signaling circuits with leading experts at this EACR Virtual Conference! This conference will focus on basic mechanisms controlling cancer cell signaling circuits at the epigenome, transcriptome, proteome, and phosphoproteome levels. The talks will also focus on therapeutic targeting of cancer cell signaling circuits by conventional and emerging pharmacological strategies, and the mechanistic aspects of post translational and transcriptional regulation of cancer cell signaling, as well as large OMICS-based global understanding of cancer cell signaling circuits.

The target audience for this conference is: scientists in academia and industry who are interested in the most recent developments in non-genetic signaling mechanisms and their roles in cancer progression and therapy resistance.

Conference Officer: Chris Iliffe;     Tél.: [N/A];     Email.: christopher.iliffe@eacr.org

cancer signaling circuits, cancer tissue phenotypes, targeted cancer therapies, cancer therapy resistance, non-genetic signaling rewiring, post-translational protein regulation, transcriptional gene regulation, cancer progression, epigenomics, transcriptomics, proteomics, phosphoproteomics, kinases and phosphatases, cancer cell plasticity, cancer research, oncology

Médecine translationnelle, essais cliniques,    Génomique et bio-informatique

TMC Academy

The purpose of this online chest radiology fellowship is to give a comprehensive course in the diagnostic work-up of lung cancer. This includes the presentation of Fleischner Society and British Thoracic Society algorithms for the work-up of solitary pulmonary lung nodules. In addition, the course will give hands-on experience in the usage of TNM 8 classification of lung cancer. Finally, the course will introduce the usage of spectral CT in the workup of lung cancer. Each module starts with a lecture. After the lecture, you will be challenged with practicing on real anonymised key cases. After and during the individual case readings there will be plenty of time for group discussion and Q&A with the expert mentor.

TMC Academy;     Tél.: [+34935500750];     Email.: academy@telemedicineclinic.com

lung, cancer, imaging, radiology

Radiologie, médecine nucléaire et radiothérapie,    Formation médicale continue (FMC)

Fusion Conferences

The 6th DNA Repair/Replication Structures & Cancer conference on 14-18 February 2024 will focus on molecular structural and mechanistic insights into dynamic complexes acting in DNA repair, replication, and inflammation and their intersections relevant to advanced cancer therapies. This fundamental information will be pivotal for pioneering research on DNA damage responses as well as for the accurate interpretation of cancer clinical data, design of clinical trials, prognosis, etiology and improving the currently low success rate for oncology drug clinical trials. Informative talks and poster sessions along with vibrant discussions will foster productive interactions, collaborations, and insights. In this conference and this area of science basic research is empowering medical advances and clinical data are unveiling basic relationships in ways that are completely changing how research and translation is being done.

Biologie moléculaire,    Génomique et bio-informatique

Deutsche Krebsgesellschaft e. V. und Stiftung Deutsche Krebshilfe

Motto: Fortschritt gemeinsam gestalten

Der Kongress umfasst kompakte und intensive Bestandsaufnahme der aktuellen Forschungsergebnisse und Situation in der Onkologie in Deutschland.

Beleuchtet werden aktuelle und künftige medizinische Entwicklungen und neue Therapien für alle Tumorentitäten. Zudem Schwerpunkte und Fragen zur Gesundheitspolitik.

Kongress- und Kulturmanagement GmbH

The European Association for the Study of the Liver (EASL)

Focusing on primary liver tumors like hepatocellular carcinoma (HCC) and biliary tract cancer (BTC), the summit explores their connection to viral infections, alcohol misuse, and metabolic disorders among other fantastic programme highlights. Bringing together clinicians, researchers, nurses, patient advocates, and industry professionals, this summit aims to address these challenges in practice. By spotlighting recent insights into tumor origins and the latest in diagnostic and treatment strategies, the EASL Liver Cancer Summit 2024 aims to contribute significantly to the advancement of liver cancer care.

European Association for Cancer Research (EACR) & American Association for Cancer Research (AACR), with support from the Irish Association for Cancer Research (IACR)

The EACR and AACR are proud to announce the 2024 edition of their joint Basic and Translational Research Conference, organised in conjunction with the IACR. The forum will highlight the latest cutting-edge advances in the understanding of the genomics, epigenetics, and molecular pathways involved in the development of pre-cancerous and cancerous lesions, and in cancer response to therapy. The scientific programme blends basic and translational research from preclinical models to patients. Topics include immunotherapy, cell-based therapies, novel/undruggable targets, drug combinations and resistance, the precancer genome, liquid biopsies, preclinical models, the tumour microenvironment, and epigenetics. The target audience is basic and translational scientists, experienced investigators and trainees at all levels with an interest in cancer development and treatment, and clinicians involved in the development of novel therapeutic approaches to treatment.

Event organiser: New Way Management;     Email.: eacr@newway-management.com

NK cell immunity, CAR T cells, solid tumours, PML nuclear bodies, AML response to therapies, synergistic cancer drug combinations, immune contexture, immunoscore, carcinogenesis, Clonal Hematopoiesis (prevention of hematologic malignancies), Fanconi anemia, stem cell attrition, genomic instability, neoadjuvant immune checkpoint blockade, cancer liquid biopsies, MYC inhibitor, preclinical models for translational research, stromal heterogeneity and spatial distribution, cell plasticity, disease mechanisms in cancer, Polycomb Epigenetic Regulators, cancer research, oncology

FomF GmbH - Forum für medizinische Fortbildung

Zertifizierte Fortbildung für ÄrztInnen der Hämatologie und Onkologie vor Ort in Frankfurt & via Livestream,03.-04.05.2024. Updates & die neuesten Leitlinien. 16 CME-Punkte wurden bei der zuständigen Ärztekammer angefragt. Jetzt informieren & buchen!

Tél.: [+49 (0) 6192 47072 00];     Email.: info@fomf.de

Formation médicale continue (FMC),    Hématologie

MDPI

In recent years, we have witnessed remarkable breakthroughs in basic cancer research, where discoveries in the genetic and epigenetic tumor make-up and tumor microenvironment have provided valuable insights into the molecular mechanisms underlying cancer initiation, progression, and therapeutic response. This newfound knowledge has laid the groundwork for novel treatment strategies and personalized approaches that hold the potential to revolutionize cancer care. This conference aspires to bring together clinicians and scientists with diverse expertise and perspectives in cancer research to interact, exchange ideas, and form new collaborations that may lead to new advancements in scientific understanding and ultimately impact patient outcomes.

Event Secretariat;     Email.: iecc2024@mdpi.com

Cancer Immunology and Immunotherapy, Cancer Biomarkers, Cancer Epidemiology and Prevention, Cancer Pathophysiology, Tumor Microenvironment, Transplant Oncology and Cancer Nursing Care, Cancer Therapy, Pediatric Oncology, Cancer Metastasis

European Society for Medical Oncology (ESMO)

The congress will constitute an occasion for specialised physicians, oncologists, scientists, industry representatives, patient advocates and nurses, from all around the world, to connect, and share their knowledge, experience, and research for the advancement of treatment of sarcoma and rare cancers. The scientific and educational programme will feature insights into the diagnosis, prognostication, management and ongoing research of patients with rare adult solid cancers, including sessions on multidisciplinary expert management, targeted therapies, precision medicine, methodological challenges, policy and guidelines, as well as sessions specifically designed for young investigators.

ESMO Meetings Operations Team;     Email.: meetings@esmo.org

sarcoma, rare cancers, drug development, molecular biology, oncology education, oncology congress, pathology, GIST, rare adult solid tumours, MDM2, desmoids

Formation médicale continue (FMC),    Radiologie, médecine nucléaire et radiothérapie

The European Association for Cancer Research (EACR)

This meeting will cover the latest exciting breakthroughs on multiple aspects of the tumour microenvironment, including the intricate interactions of cancer cells with the immune system and with specific stromal cells in multiple organs. We will also highlight novel insights into tumour-host interactions including changes in metabolism, the nervous system and response to therapy.

Join us to hear from world experts who are at the forefront of the tumour microenvironment field, sharing their latest discoveries and insights about this cutting-edge research and its implications for novel cancer therapies. Featured topics include the role of inflammation and immunity in tumour progression and metastasis, organ-specific stromal cells that support tumour progression, metabolic changes in the tumour microenvironment, tumour-host interactions in response to therapy, cancer interactions with the nervous system, and dormancy and metastasis.

The target audience for this conference is: scientists, postdocs, and graduate students interested in multiple aspects of cancer biology, immunology, and therapeutics; industry scientists interested in translational research and novel therapeutic approaches; and journal editors interested in cutting-edge cancer biology.

Conference Officer: Hannah Baars;     Email.: hannah.barrs@eacr.org

tumour ecosystem, carcinogenesis, metastasis, tumour therapy response, novel therapeutics, reciprocal cancer-stroma interactions, tumour progression, organ-specific stromal cells, tumour-host interactions, nervous system interactions, tumour dormancy, metastasis progression, ECM remodelling, therapy resistance, immune cell heterogeneity, stromal plasticity, immune plasticity, fibroblast interactions, treatment resistance, cancer research, oncology

The European Association for Cancer Research

This meeting will cover the latest exciting breakthroughs on multiple aspects of the tumour microenvironment, including the intricate interactions of cancer cells with the immune system and with specific stromal cells in multiple organs. We will also highlight novel insights into tumour-host interactions including changes in metabolism, the nervous system and response to therapy. Join us to hear from world experts who are at the forefront of the tumour microenvironment field, sharing their latest discoveries and insights about this cutting-edge research and its implications for novel cancer therapies. Featured topics include the role of inflammation and immunity in tumour progression and metastasis, organ-specific stromal cells that support tumour progression, metabolic changes in the tumour microenvironment, tumour-host interactions in response to therapy, cancer interactions with the nervous system, and dormancy and metastasis.

Email.: hannah.barrs@eacr.org

tumour ecosystem, carcinogenesis, metastasis, tumour therapy response, novel therapeutics, reciprocal cancer-stroma interactions, tumour progression, organ-specific stromal cells, tumour-host interactions, nervous system interactions, tumour dormancy, metastasis progression, ECM remodelling, therapy resistance, immune cell heterogeneity, stromal plasticity, immune plasticity, fibroblast interactions, treatment resistance, cancer research, oncology

ITOC is organised by the WMA GmbH in scientific cooperation with the ITOC Association, the Tumor Centre in Munich (TZM), the Wolfgang Wilmanns Stiftung (WWS), the German Cancer Consortium (DKTK), the Chinese American Hematologist and Oncologist Network (

The main goal of the series of ITOC conferences is to provide a unique platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and latest findings to advance the oncology drug development and delivery.

Event Secretariat;     Tél.: [+431405138318];     Email.: itoc@wma.co.at

Basic Tumor Immunology, New Targets and New Leads, Exploiting B Cells and Other Cell Types, Microbiome, Adjuvant vs Neoadjuvant IO Treatment, Combination Therapies, Immuno-Monitoring, Reaching New Grounds in Cellular Therapies, Cell therapies in Hematologic Oncology, Cell Therapies in Solid Oncology

Immunologie et Allergie,    Médecine translationnelle, essais cliniques

The TWC is an international conference that brings together leading experts in the field from around the world. Our goal is to provide a platform for researchers, students, clinicians, and industry professionals to share their knowledge, learn and discuss the latest advancements in this exciting field.

Theranostic, Radiomolecular Precision Medicine, RPM, Radioisotopes, Prostate Cancer, Radiotherapy, Tumor Microenvironment, NET, Radioisotopes, Congress

Radiologie, médecine nucléaire et radiothérapie,    Pharmacologie et développement des médicaments

Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie

GEMEINSAM stärker – Stronger together ist das Thema unserer Frühjahrstagung 2024. Nicht nur die letzten Jahre haben unser Denken durch die COVID-Pandemie verändert. Auch schon davor hat sich immer klarer gezeigt, dass wir GEMEINSAM stärker sind. GEMEINSAM, was die Erforschung, das Behandeln und schließlich auch in immer mehr Fällen das Besiegen der Erkrankungbetrifft. GEMEINSAM ist hier ebenso interdisziplinär zu verstehen, und zwar über alle Berufsgruppen hinweg: dazu zählt die Pflege genauso wie die klinische Psychologie, die Studienkoordinator*innen, Grundlagenforschung und klinische Forschung, aber natürlich auch unsere Patient*innen.

Sekretariat der OeGHO;     Email.: office@oegho.at

Frühjahrstagung, Hämatologie, Onkologie, OeGHO, AHOP

Binaytara foundation

The 2024 International Cancer Congress (ICC2024) is the 6th annual oncology conference organized by the Binaytara Foundation in Janakpurdham, Nepal. ICC2024 meeting will provide an opportunity to hear from the leading national and international experts on gastrointestinal malignancies and breast cancer.

Tél.: [425-616-0572];     Email.: yoadan.h@binayfoundation.org

Hematologists, Oncologists, Surgeons, Hematologic disorders, Breast cancer, oncology, patology

European Molecular Biology Organization – EMBO

The European Association for the Study of the Liver (EASL)

After years of stagnation, a paradigm shift has occurred in the therapy of hepatobiliary malignancies: immune-oncology based combinations and new options in the second line revolutionized the treatment of patients with hepatocellular carcinoma, while biliary cancers – endowed with a genuinely high frequency of targetable lesions – evolved as a role model for precision oncology. These developments have generated a growing need for clinicians, pathologists and translational scientists to gain an in-depth understanding of diagnostic and clinical strategies that facilitate the implementation of individualized treatment concepts in hepato-oncology. The EASL school on “Personalized medicine in hepatobiliary malignancies” transitions fluently between molecular pathology diagnostics and clinical translation and provides room and space to foster interdisciplinary exchange. Under the guidance of experts in the field (liver pathologists, clinical and basic hepato-oncologists), students will gain confidence in the interpretation of molecular diagnostics reports and perform group work to build innovative treatment concepts for patients with hepatobiliary cancers. In addition to short lectures, panel discussions and a “live microscopy session”, the school features thought-provoking discourses on the diagnostic and therapeutic future of hepato-oncology.

The European Association for Cancer Research

This revamped iteration of our renowned Cancer Genomics series will cover the latest exciting developments in the fields of genomics and bioinformatics including machine learning and AI, single-cell and spatial analysis of cancers, cell plasticity, cancer immunity genomics, data integration and convergence, epigenetics, and genomic instability. Featuring an exceptional international faculty, extensive networking opportunities and a limited number of in-person participants, this conference will provide both the possibility and intimate setting for top quality scientific interaction. We look forward to welcoming you to the Weizmann Institute of Science for this exciting meeting!

Conference Officer: Chris Iliffe;     Email.: christopher.iliffe@eacr.org

multiomics, computational biology, machine learning, artificial intelligence, single-cell analysis, spatial analysis, cell plasticity, cancer immune genomics, data integration, data convergence, epigenetics, genomic instability, cancer immunology, molecular pathology, cancer transcriptomes, cell tracking, cancer evolution, immune evasion, the cancer genome, neoantigenic landscape, antitumour t-cell response, 3D analysis, translational research, cancer research, oncology

European Society of Veterinary Oncology

Spectus Conferences

The Organizing Committee of International Conference on Cancer and Oncology Research invite you to participate in the Cancer Conference, which will be held during May 30-31, 2024 at Rome, Italy The main theme of conference is “Exploring the Recent Research and Advancements in Cancer and Oncology Research”. This Conference will provide a unique opportunity for researchers, healthcare practitioners, paramedics and trauma care specialists from around the world to communicate and share innovative thoughts and practices designed to optimize patient care.

Tél.: [03023084943];     Email.: spec-cancer@spectusconferences.org

Skin Cancers Tumor heterogeneity and Cancer Metastasis Translational Biology to Medicine in Innovative oncology Immune Responses & DNA Repair - Cancer Fields Cancer Genetics Cancer Therapy & Treatments Surgical Oncology Single-cell and Spatial Multiomics in Cancer Research Cancer Prevention & Research Cancer Signaling Next Generation Cancer Models Antibody-based Therapeutics Against Cancer Radiation Oncology

The European Association for Cancer Research

The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024) is a four day congress dedicated to basic, preclinical and translational cancer research across a wide breadth of topics. It will highlight the latest research and bring together the cancer research community to inspire innovation and build knowledge, connections and collaborations. The programme includes cutting-edge scientific talks on various topics, industry symposia and spotlights, educational sessions, meet-the-expert panels, career discovery sessions, and a vast poster display. Topics to be covered include: modulating the tumour microenvironment; drug resistance; mechanism-based clinical trials; precision cancer medicine in the post-genomic era; senescence, dormancy, and related cell states; metabolism and cancer; cell-based therapies; spatial analysis of tumours/spatial transcriptomics; mechanical forces of cancer; mechanisms of tumour metastases; targeting mitochondria in cancer; liquid biopsies; drugging tumour suppressor genes; imaging the tumour microenvironment; making cold tumours hot; drugging the RAS Pathway; modeling cancer; and aging, gender, and cancer.

Event Organisers: New Way Management;     Email.: eacr@newway-management.com

cancer research, cancer research conference, oncology, cancer models, liquid biopsies, tumour microenvironment, tumour metastasis, cancer metabolism, cancer cell states, cell-based therapies, drug resistance, genomics, spatial transcriptomics

Deutsche Gesellschaft für Radioonkologie e.V. (German Society for Radiation Oncology)

At the annual congress of the German Society of Radiation Oncology (DEGRO), all those working in radiation oncology have the opportunity to discuss all aspects important for the development of radiation oncology in a concentrated form and thus come to a broad exchange of knowledge.

Kongressorganisation;     Tél.: [+49 3643 2468-126];     Email.: degro-registrierung@KUKM.DE

radiooncology, radiotherapy, nuclear medicine, oncology, radiology, radiation, hematology, medicine, nuclear physicians, medical technologist for radiology

Radiologie, médecine nucléaire et radiothérapie,    Hématologie

FomF GmbH - Forum für medizinische Fortbildung

Zertifizierte Fortbildung für ÄrztInnen der Hämatologie und Onkologie vor Ort in Hamburg & via Livestream, 21.-22.06.2024. Updates & die neuesten Leitlinien. 16 CME-Punkte wurden bei der zuständigen Ärztekammer angefragt. Jetzt informieren & buchen!

Tél.: [+49 (0) 6192 47072 00];     Email.: info@fomf.de

Formation médicale continue (FMC),    Hématologie

European Society for Medical Oncology (ESMO)

Brought to you by the European Society for Medical Oncology (ESMO), the congress will be the place to present very impactful new data in GI oncology. The scientific sessions will be complemented with high quality educational sessions and excellent networking opportunities.

In recent years we have seen remarkable progress in the treatment options available for patients with GI cancers and ESMO is committed to ensuring that there is a clear roadmap to help facilitate the implementation of new practice changing discoveries in the clinic for the benefit of all patients with GI cancers and whose wellbeing is our primary concern. The ESMO Gastrointestinal Cancers Congress will provide global visibility for original clinical and translational research.

Tél.: [+41 (0)91 973 19 62];     Email.: gicongress@esmo.org

Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Pancreatic Cancer, Biliary Tract Cancer, Neuroendocrine Tumors, Colon Cancer, Rectal Cancer, GIST, Anal Cancer, Gastrointestinal Cancers

Gastro-entérologie,    Médecine translationnelle, essais cliniques

European Molecular Biology Organization – EMBO

Fields Institute

This workshop aims to showcase the state-of-the-art mathematical and computational models that are in use in mathematical oncology, with a particular focus on the fourteen hallmarks of cancer. New modeling challenges arise from these hallmarks. Some of the hallmarks relate to the characteristics of the cancer cells themselves (sub-cellular and cellular level), while others include more global effects such as blood circulation, the immune response, the effect and role of the microenvironment, mechanical forces, and the microbiome. Matching the biological diversity of the cancer hallmarks, is the diversity of mathematical approaches and techniques that have been used and are in use to give insight into the growth and spread of cancer – for example, continuum and discrete models; ordinary and partial differential equation models; individual-based and agent-based models; hybrid models; deterministic and stochastic approaches; analytical and computational approaches. Many of these processes act on very different spatial and temporal scales. Hence a new integrated multiscale mathematical modeling framework is needed to include new aspects and insights, such as spatial stochastic models and local and non-local partial differential equation models.

Simulation,    Biologie des systèmes

Conventus Congressmanagement & Marketing GmbH

Conventus Congressmanagement & GmbH;     Email.: conferencemarketing@conventus.de

European Helicobacter and Microbiota Study Group

The European Helicobacter and Microbiota Study Group (EHMSG) is a multidisciplinary group composed of representatives from most countries of the EU. It was founded in 1987 by a collaboration of pioneers in the field of Helicobacter and expanded its remit in 2016 to embrace the collective gastrointestinal microbiota. This includes dissemination of medical, scientific and technical information in order to promote health and decrease the burden of digestive diseases.

Each year, EHMSG hosts a conference consisting of a one-day postgraduate course followed by a 2-day workshop.

Event Secretariat;     Tél.: [+431405138318];     Email.: workshop@ehmsg.org

Helicobacter, Microbiota, IBD, FMT

Gastro-entérologie,    Médecine (en général), médecine interne

Fields Institute

This workshop aims to take a closer look at how mathematical and computational models can help answer clinically relevant questions and enhance multimodal treatments. Currently, a wide range of modelling approaches study cancer and have a crucial role in treatment delivery from answering questions related to cancer biology and treatment efficacy to directly helping with treatment delivery. In this workshop, we would like to bring together clinicians, biomedical experts, experimentalists, and mathematicians to explore some of the relevant questions on multimodal treatment modelling, efficacy, optimization, drug resistance and clinical delivery.

Simulation,    Biologie des systèmes

Fields Institute

This workshop explores research in methods aimed at connecting mathematical models of cancer evolution and clinical data. It focuses on ecology and evolution of cancer. Traditionally, ecology and evolution have been the most “mathematical” (and perhaps the first mathematical) areas of biology. Mathematical contributions to these fields made in the 20th century are now fundamental parts of scientific knowledge. More recently, methods of ecology and evolution have found their way into oncology, bridging traditional molecular biology and mathematics including stochastic processes, dynamical systems, and nonlinear partial differential equations. New biological challenges lead to difficult mathematical problems and beautiful solutions, which are both innovative mathematically and impactful from the point of view of public health. These will be the focus of the proposed workshop .

Simulation,    Biologie des systèmes

Fields Institute

Immunotherapies have revolutionized treatments for several types of cancers, but have been met with clinical trial failures in others. The idea of eliciting an immune response against a tumour is old, but we are only just beginning to harness the potential of the immune system to treat both solid and liquid tumours. To improve immunotherapeutic approaches requires understanding how the immune system interacts around and within a tumour, allowing us to establish effective immunotherapeutic protocols. Mathematical modelling can help identify the mechanisms at the heart of immunotherapeutic efficacy and design successful therapeutic regimens. Close collaboration between experimentalists, clinicians, and quantitative researchers in academia and industry is required to forward models for implementation. This workshop will focus on tightening the links between researchers in different fields to fuel immunotherapy success.

Simulation,    Biologie des systèmes